NCT06830044View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Milsaperidone

Oral milsaperidone

DRUG

Placebo

Oral placebo

Trial Locations (2)

72211

RECRUITING

Vanda Investigational Site, Little Rock

75080

RECRUITING

Vanda Investigational Site, Richardson

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY